NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MediLink Therapeutics

MediLink Therapeutics

Private
SuzhouHealthcare & Life Scienceshttps://medilinkthera.com/

Last Round

Series B

Mar 14, 2022

Total Funding Raised

$120M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

MediLink Therapeutics is a biopharmaceutical company that develops innovative antibody-drug conjugates (ADC) for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADConcology therapeuticslinker-payload technologycancer drug developmentbiotech licensingclinical-stage biotechtargeted cancer therapybiopharma partnershipcytotoxic payloaddrug discovery platformprecision medicinenext-gen ADCsbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MediLink Therapeutics Comparables

Compare MediLink Therapeutics with similar companies based on industry and business-model similarity.

MediLink Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Duality Biotherapeutics Inc
93%
Aimed Bio Inc.
82%
LigaChem Biosciences
79%

MediLink Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 14, 2022
Series AMar 1, 2021

Key People

Founding team and executive leadership

xue tongtong

CEO

Executive Team

Jason Li

Chief Financial Officer

Executive Team

MediLink Therapeutics Investors

Notable investors and investment history

MediLink Therapeutics investors
InvestorRounds
HighLight CapitalSeries B
Loyal Valley CapitalSeries B, Series A
Highlight CapitalSeries B
LYFE CapitalSeries B
Legend CapitalSeries B
Qiming Venture PartnersSeries B, Series A
Panacea Venture HealthcareSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 76% MoM.

  • Jul 1, 2025

    Dr. Weichang Zhou appointed as new CTO.

MediLink Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MediLink Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MediLink Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range61
Year Founded2020
Last FundingMar 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.